Uses
AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Source: US FDA prescribing information
- Presentations
- 2
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Erenumab is a prescription medicine indicated for the preventive treatment of migraine in adults. It is available as injection for subcutaneous use. MedsAcross supplies Erenumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- ATC classification
- N02CD01 Erenumab · Antimigraine, subgroup N02CD
- US FDA first approval
- 17 May 2018
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Subcutaneous
- Dosage forms
- Injection
- Biologic
- Yes
- Identifiers
- UNII I5I8VB78VTRxCUI 2045613CAS 1582205-90-0DrugBank DB14039Q28209017
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Source: US FDA prescribing information
Dosing overview
For subcutaneous use only. Recommended dosage is 70 mg once monthly, some patients may benefit from a dosage of 140 mg once monthly. Administer in the abdomen, thigh, or upper arm subcutaneously. See Dosage and Administration for important administration instructions
Source: US FDA prescribing information
Contraindications
AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Source: US FDA prescribing information
Warnings and precautions
Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of AIMOVIG and initiate appropriate therapy. Hypersensitivity reactions can occur within hours to more than one week after administration. Constipation with Serious Complications: Serious complications of constipation may occur. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur.
Source: US FDA prescribing information
Side effects
The following serious adverse reactions are described below and elsewhere in the labeling: Hypersensitivity Reactions Constipation with Serious Complications Hypertension Raynaud's Phenomenon The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation.
Source: US FDA prescribing information
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. If removed from the refrigerator, AIMOVIG should be kept at room temperature (up to 25°C [77°F]) in the original carton and must be used within 7 days. Throw away AIMOVIG that has been left at room temperature for more than 7 days. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
2 presentations of Erenumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Aimovig 140 mg/1 mL injectionSubcutaneous Cold chain | Amgen | US FDA | Available on request |
| Aimovig 70 mg/1 mL injectionSubcutaneous Cold chain | Amgen | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions
Conditions linked to Erenumab in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Erenumab available for export from India?
Yes, on request. MedsAcross lists 2 presentations of Erenumab and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Erenumab have?
The catalogue lists 1 brand names for Erenumab, including Aimovig.
Is Erenumab approved by the US FDA?
Yes. The US FDA first approved Erenumab on 17 May 2018, according to Drugs@FDA.
Is Erenumab authorised in the European Union?
Yes. Erenumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Erenumab need cold chain shipping?
At least one listed presentation of Erenumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Which ATC class is Erenumab in?
Erenumab is classified under ATC code N02CD01 (Erenumab).
References
- AIMOVIG prescribing information (Amgen). U.S. National Library of Medicine, DailyMed. Retrieved 14 July 2026
- Aimovig: European public assessment report (EPAR). European Medicines Agency. Retrieved 5 October 2026
Request Erenumab for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.